|Geron stock price Jan. 2-8|
Tuesday, January 08, 2013
The stock price of Biotime, Inc., of Alameda, Ca., shot up more than 12 percent today following the announcement of a complex deal that will give it the stem cell assets of Geron Corp., the first firm to launch a clinical trial for an hESC therapy.
BioTime stock closed at $3.88, up 43 cents or 12.46 percent. That followed a 9.6 percent gain yesterday. Geron's stock closed at $1.63, up three cents or 1.9 percent.
News coverage of the deal was light with our tracking showing only one story so far today on The Scientist magazine web site.Sphere: Related Content
Posted by David Jensen at 1:45 PM